Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

Autor: Chalmers, JR, Thomas, KS, Apfelbacher, C, Williams, HC, Prinsen, CA, Spuls, PI, Simpson, E, Gerbens, LAA, Boers, M, Barbarot, S, Stalder, JF, Abuabara, K, Aoki, V, Ardeleanu, M, Armstrong, J, Bang, B, Berents, TL, Burton, T, Butler, L, Chubachi, T, Cresswell-Melville, A, DeLozier, A, Eckert, L, Eichenfield, L, Flohr, C, Futamura, M, Gadkari, A, Gjerde, ES, van Halewijn, KF, Hawkes, C, Howells, L, Howie, L, Humphreys, R, Ishii, HA, Kataoka, Y, Katayama, I, Kouwenhoven, W, Langan, SM, Leshem, YA, Merhand, S, Mina-Osorio, P, Murota, H, Nakahara, T, Nunes, FP, Nygaard, U, Nygårdas, M, Ohya, Y, Ono, E, Rehbinder, E, Rogers, NK, Romeijn, GLE, Schuttelaar, MLA, Sears, AV, Simpson, MA, Singh, JA, Srour, J, Stuart, B, Svensson, Å, Talmo, G, Talmo, H, Teixeira, HD, Thyssen, JP, Todd, G, Torchet, F, Volke, A, von Kobyletzki, L, Weisshaar, E, Wollenberg, A, Zaniboni, M

This is the report from the fifth meeting of the Harmonising Outcome Measures for Eczema initiative (HOME V). The meeting was held on 12-14 June 2017 in Nantes, France, with 81 participants. The main aims of the meeting were (i) to achieve consensus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::c8c44e6d89d34ae1566e6cfcce58ea90

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks.

Autor: Paller AS; Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.; Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois., Mendes-Bastos P; Dermatology Center, Hospital CUF Descobertas, Lisboa, Portugal., Siegfried E; Department of Pediatrics, St Louis University School of Medicine, St Louis, Missouri., Eichenfield LF; Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, California.; Department of Dermatology, UC San Diego School of Medicine, University of California, San Diego.; Department of Pediatrics, UC San Diego School of Medicine, University of California, San Diego., Soong W; AllerVie Health-Alabama Allergy & Asthma Center and Clinical Research Center of Alabama, Birmingham., Prajapati VH; Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.; Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.; Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.; Skin Health & Wellness Centre, Calgary, Alberta, Canada.; Dermatology Research Institute, Calgary, Alberta, Canada.; Probity Medical Research, Calgary, Alberta, Canada., Lio P; Medical Dermatology Associates of Chicago, Chicago, Illinois., Simpson EL; Department of Dermatology, Oregon Health & Science University, Portland., Raymundo EM; AbbVie Inc, North Chicago, Illinois., Suravaram S; AbbVie Inc, North Chicago, Illinois., Hu X; AbbVie Inc, North Chicago, Illinois., Yang Y; AbbVie Inc, North Chicago, Illinois., Huang X; AbbVie Inc, North Chicago, Illinois., Calimlim BM; AbbVie Inc, North Chicago, Illinois., Platt AM; AbbVie Inc, North Chicago, Illinois., Su JC; Department of Dermatology, Monash University, Melbourne, Australia.; Eastern Health and MCRI, University of Melbourne, Melbourne, Australia., Zheng M; Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China., Yamamoto-Hanada K; Allergy Center, National Center for Child Health and Development, Tokyo, Japan., Teixeira HD; AbbVie Inc, North Chicago, Illinois., Irvine AD; Clinical Medicine, Trinity College Dublin, Dublin, Ireland.

Publikováno v: JAMA dermatology [JAMA Dermatol] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23.

Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis®.

Autor: Silverberg JI; From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA., de Bruin-Weller M; Department of Dermatology and Allergology, Utrecht, Netherlands., Calimlim BM; AbbVie Inc., Chicago, Illinois, USA., Hu X; AbbVie Inc., Chicago, Illinois, USA., Ofori SA; AbbVie Inc., Chicago, Illinois, USA., Platt AM; AbbVie Inc., Chicago, Illinois, USA., Teixeira HD; AbbVie Inc., Chicago, Illinois, USA., Eyerich K; Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany., Thyssen JP; Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.

Publikováno v: Dermatitis : contact, atopic, occupational, drug [Dermatitis] 2024 May-Jun; Vol. 35 (3), pp. 266-274. Date of Electronic Publication: 2023 Dec 18.